In August 2022, T-DXd was approved for the treatment of patients with HER2-low MBC or HER2-mutant NSCLC (NCT03734029, NCT03505710, and NCT04644237), becoming the first FDA-approved drug to treat HER2-mutant NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.